Altus Formulation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

11th Annual PODD Drug Delivery Conference Announces 2021 Keynotes  The Conference Forum is pleased to announce that the 11th annual PODD: Partnership Opportunities in Drug Delivery conference will take place in-person on October 28-29, 2021, at The Westin Boston Seaport District in Boston, MA. PODD brings together the R&D industry and the drug delivery community to figure out the best routes of delivering therapeutics and reducing the burden to patients. PODD 2021 kicks off with Barbara Lueckel, PhD, Global Head of Research Technologies Partnering, Roche Pharma Partnering, followed by Dr Rob...

Abuse Deterrent Formulation Technologies Market Research Report, Growth Trends and Competitive Analysis 2021-2027    Abuse Deterrent Formulation Technologies Market Size 2021 by Product Sales, Revenue, Price, Market Share, Growth Opportunity and Forecast to 2024 Research Report I Top key players- Acura Pharmaceuticals, Altus Formulation, BioDelivery Sciences International, Teva Pharmaceutical, Elysium Therapeutics, Grünenthal, Intellipharmaceutics, Purdue Pharma, TITAN Pharmaceutical infinityMay 16, 2021 A new analytical data on the global Abuse Deter...

DGAP-News: Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA vom 15.04.2021, 13:00 Uhr Bild: pixabay.com Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA 15.04.2021 / 13:00 Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA New USA Patent Complements Existing Global Flexitab Portfolio LAVAL, QC / ACCESSWIRE / April 15, 2021 / Altus Formulation Inc. ("Altus") today announced that its patent application US 2020029785 covering all Flexitab Breakable Extended R...

Altus Formulation Inc.: Altus Formulation Announces Allowance of New Flexitab Technology Patent in USA New USA Patent Complements Existing Global Flexitab Portfolio LAVAL, QC / ACCESSWIRE / April 15, 2021 / Altus Formulation Inc. ("Altus") today announced that its patent application US 2020029785 covering all Flexitab Breakable Extended Release Tablets has been allowed by the United States Patent and Trademark Office. The new patent is expected to provide protection to Flexitab products in the USA until 2038. Speaking about the new patent Dr. Damon Smith CEO of Altus said; "We are very pleas...

Altus Formulation Inc.: Cadila Pharmaceuticals and Altus Formulation Announce Successful Clinical Studies with TramaFlex Breakable Extended-Release Tablets tm Modified Release Technology Platform: New Safer to Use Value Added Tablets AHMEDABAD, INDIA and LAVAL, QC / ACCESSWIRE / January 27, 2021 / Cadila Pharmaceuticals Limited (" Cadila") and Altus") today announced the successful completion of human clinical studies with TramaFlex TM breakable extended-release (ER) tablets, a novel value-added once-daily formulation of tramadol hydrochloride for the improved treatment of patients with mod...